Breaking Down FDA’s New Remote Monitoring Strategy

Published date16 April 2021
Subject MatterManufacturers,Biologics,Teleconferences,Inspections,Surveillance,GAO,Compliance,Public Health Emergency,FD&C Act,Coronavirus/COVID-19,Pre-approval,FDA,Final Guidance
AuthorAllison Fulton,Eva Schifini
Law FirmSheppard Mullin Richter & Hampton LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT